Regulatory approval

Published by the European Medicines Agency. Approved

The European Medicines Agency (EMA) has authorized brentuximab vedotin in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) for the treatment of adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III, or Stage IV Hodgkin lymphoma (HL).

This is written in the approval document as:

ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD).

Citation

Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised March 2026. Accessed August 2, 2026.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) CD30 + Hodgkin Lymphoma Brentuximab vedotin, Cyclophosphamide, Dacarbazine, Dexamethasone, Doxorubicin, Etoposide

Contributions

Date Contributor Description
2026-08-02 Van Allen lab Initial curation of into moalmanac-db
2025-06-02 European Medicines Agency Indication received approval from the European Commission.